Construcción de cepas de pichia pastoris portadoras del DNAc de la hormona del crecimiento bovino

Tesis (Maestría en Ciencias con Especialidad en Biología Molecular e Ingeniería Genética) UANLUANLhttp://www.uanl.mx

Genetic variants in KCNJ11, TCF7L2 and HNF4A are associated with type 2 diabetes, BMI and dyslipidemia in families of Northeastern Mexico: A pilot study

The aim of the present study was to investigate whether genetic markers considered risk factors for metabolic syndromes, including dyslipidemia, obesity and type 2 diabetes mellitus (T2DM), can be applied to a Northeastern Mexican population. A total of 37 families were analyzed for 63 single nucleotide polymorphisms (SNPs), and the age, body mass index (BMI), glucose tolerance values and blood lipid levels, including those of cholesterol, low‑density lipoprotein (LDL), very LDL (VLDL), high‑density lipoprotein (HDL) and triglycerides were evaluated. Three genetic markers previously associated with metabolic syndromes were identified in the sample population, including KCNJ11, TCF7L2 and HNF4A. The KCNJ11 SNP rs5210 was associated with T2DM, the TCF7L2 SNP rs11196175 was associated with BMI and cholesterol and LDL levels, the TCF7L2 SNP rs12255372 was associated with BMI and HDL, VLDL and triglyceride levels, and the HNF4A SNP rs1885088 was associated with LDL levels (P\u3c0.05)

Uridine 5'‑diphospho‑glucronosyltrasferase: Its role in pharmacogenomics and human disease (Review)

Abstract. Biotransformation is an enzyme-catalyzed process in which the body converts endogenous compounds, xenobiotics and toxic substances into harmless or easily excreted metabolites. The biotransformation reactions are classified as phase I and II reactions. Uridine 5'-diphospho (UDP)-glucuronosyltransferases (UGTs) are a superfamily of phase II enzymes which have roles in the conjugation of xenobiotics or endogenous compounds, including drugs and bilirubin, with glucuronic acid to make them easier to excrete. The method the human body uses to achieve glucuronidation may be affected by a large interindividual variation due to changes in the sequences of the genes encoding these enzymes. In the last five years, the study of the genetic variants of the UGTs at a molecular level has become important due to its association with several diseases and the ability to predict adverse events due to drug metabolism. In the present review, the structure and the prominent genetic variants of the UGT1A subfamily and their metabolic and clinical implications are described

Nanoparticles for death‑induced gene therapy in cancer (Review)

Abstract. Due to the high toxicity and side effects of the use of traditional chemotherapy in cancer, scientists are working on the development of alternative therapeutic technologies. An example of this is the use of death-induced gene therapy. This therapy consists of the killing of tumor cells via transfection with plasmid DNA (pDNA) that contains a gene which produces a protein that results in the apoptosis of cancerous cells. The cell death is caused by the direct activation of apoptosis (apoptosis-induced gene therapy) or by the protein toxic effects (toxin-induced gene therapy). The introduction of pDNA into the tumor cells has been a challenge for the development of this therapy. The most recent implementation of gene vectors is the use of polymeric or inorganic nanoparticles, which have biological and physicochemical properties (shape, size, surface charge, water interaction and biodegradation rate) that allow them to carry the pDNA into the tumor cell. Furthermore, nanoparticles may be functionalized with specific molecules for the recognition of molecular markers on the surface of tumor cells. The binding between the nanoparticle and the tumor cell induces specific endocytosis, avoiding toxicity in healthy cells. Currently, there are no clinical protocols approved for the use of nanoparticles in death-induced gene therapy. There are still various challenges in the design of the perfect transfection vector, however nanoparticles have been demonstrated to be a suitable candidate. This review describes the role of nanoparticles used for pDNA transfection and key aspects for their use in death-induced gene therap

Detection of Turner Syndrome by Quantitative PCR of SHOX and VAMP7 Genes

Turner Syndrome (TS) is an unfavorable genetic condition with a prevalence of 1:2500 in newborn girls. Prompt and effective diagnosis is very important to appropriately monitor the comorbidities. The aim of the present study was to propose a feasible and practical molecular diagnostic tool for newborn screening by quantifying the gene dosage of the SHOX, VAMP7, XIST, UBA1, and SRY genes by quantitative polymerase chain reaction (qPCR) in individuals with a diagnosis of complete X monosomy, as well as those with TS variants, and then compare the results to controls without chromosomal abnormalities. According to our results, the most useful markers for these chromosomal variants were the genes found in the pseudoautosomic regions 1 and 2 (PAR1 and PAR2), because differences in gene dosage (relative quantification) between groups were more evident in SHOX and VAMP7 gene expression. Therefore, we conclude that these markers are useful for early detection in aneuploidies involving sex chromosomes

Genetic variants in KCNJ11, TCF7L2 and HNF4A are associated with type 2 diabetes, BMI and dyslipidemia in families of Northeastern Mexico: A pilot study

Abstract. The aim of the present study was to investigate whether genetic markers considered risk factors for metabolic syndromes, including dyslipidemia, obesity and type 2 diabetes mellitus (T2DM), can be applied to a Northeastern Mexican population. A total of 37 families were analyzed for 63 single nucleotide polymorphisms (SNPs), and the age, body mass index (BMI), glucose tolerance values and blood lipid levels, including those of cholesterol, low-density lipoprotein (LDL), very LDL (VLDL), high-density lipoprotein (HDL) and triglycerides were evaluated. Three genetic markers previously associated with metabolic syndromes were identified in the sample population, including KCNJ11, TCF7L2 and HNF4A. The KCNJ11 SNP rs5210 was associated with T2DM, the TCF7L2 SNP rs11196175 was associated with BMI and cholesterol and LDL levels, the TCF7L2 SNP rs12255372 was associated with BMI and HDL, VLDL and triglyceride levels, and the HNF4A SNP rs1885088 was associated with LDL levels (P<0.05)

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Background: The genetic variation underlying atorvastatin (ATV) pharmacokinetics was evaluated in a Mexican population. Aims of this study were: 1) to reveal the frequency of 87 polymorphisms in 36 genes related to drug metabolism in healthy Mexican volunteers, 2) to evaluate the impact of these polymorphisms on ATV pharmacokinetics, 3) to classify the ATV metabolic phenotypes of healthy volunteers, and 4) to investigate a possible association between genotypes and metabolizer phenotypes. Methods: A pharmacokinetic study of ATV (single 80-mg dose) was conducted in 60 healthy male volunteers. ATV plasma concentrations were measured by high-performance liquid chromatography mass spectrometry. Pharmacokinetic parameters were calculated by the non-compartmental method. The polymorphisms were determined with the PHARMAchip® microarray and the TaqMan® probes genotyping assay. Results: Three metabolic phenotypes were found in our population: slow, normal, and rapid. Six gene polymorphisms were found to have a significant effect on ATV pharmacokinetics: MTHFR (rs1801133), DRD3 (rs6280), GSTM3 (rs1799735), TNFα (rs1800629), MDR1 (rs1045642), and SLCO1B1 (rs4149056). The combination of MTHFR, DRD3 and MDR1 polymorphisms associated with a slow ATV metabolizer phenotype. Conclusion: Further studies using a genetic preselection method and a larger population are needed to confirm these polymorphisms as predictive biomarkers for ATV slow metabolizers

Heredabilidad de la obesidad en el noreste de México. Estudio basado en el índice de masa corporal de diadas (madre-hijo). 6 Cuarta época, año 2 (2018) septiembre-diciembre. Diario de Campo. Nombrar y contar. Visibilidad estadística de las poblaciones afromexicanas

El propósito de este estudio de genética cuantitativa consiste en estimar la heredabilidad (h2) del índice de masa corporal (IMC) en 2 840 diadas madre-descendiente con residencia en cinco estados del noreste de México. La h2 total entre los cinco estados fue de 51.6% y no se encontraron diferencias entre ellas (X2 = 5.24, p = 0.26). En conclusión, desde un punto de vista de la epidemiologia genética, cualquiera de estas poblaciones es ideal para la búsqueda de genes candidatos no sólo de la obesidad (OB), sino de otras enfermedades multifactoriales.Alcalde-Rabanal, Jacqueline Elizabeth et al. (2018). “The complex scenario of obesity, diabetes and hypertension in the area of influence of primary healthcare facilities in Mexico”. PLoS One. 13 (1), e0187028. doi: 10.1371/journal.pone.0187028Barquera, Simón y White, Mariel (2018). “Treating obesity seriously in Mexico: Realizing, much too late, action must be immediate”. Obesity Research, 26 (10), pp. 1530-1531.Bastarrachea, Raúl et al. (2007). “Heritability and genetic correlations of metabolic disease-related phenotypes in Mexico: Preliminary report from the GEMM Family Study”, Human Biology, 79 (1), pp. 121-129.Calderón-Garcidueñas, Ana Laura et al. (2008). “Genetic structure of Mexican mestizo women with breast cancer based on three STR loci”. Human Biology, 20 (2), pp. 191-193.Candelero-Juárez, Yadira et al. (2016). “Mínima contribución genética de la obesidad y mínima concordancia entre la percepción materna del peso del hijo (PMPH) con el estado nutricio en Tabasco, México”.Medicina de Torreón, 8 (2), pp. 16-19.Center for Disease and Control Prevention. Overweight and Obesity (mayo, 2018). Recuperado de: https://www.cdc.gov/obesity/index.htmlCerda-Flores, Ricardo Martín et al. (2002). “Maximum likelihood estimates of admixture in Northeastern Mexico using 13 short tandem repeat loci”, American Journal of Human Biology, 14 (4), pp. 429-439._____ (2004). “Epidemiologia genética de la obesidad en el noreste de México. Estimación de la heredabilidad en adolescentes”, Revista de Investigación Clínica, 56 (6), pp. 804-805._____ (2013). “Genetic structure of Mexican Mestizos with type 2 diabetes mellitus based on three STR loci”,Gene, 525 (1), pp. 41-46.Dávila-Rodríguez, Martha I. et al. (2005). “Epidemiología genética de la obesidad en el noreste de México. Búsqueda de familias nucleares informativas”, Gaceta Médica de México, 141 (3), pp. 243-246.Del Río-Navarro, Blanca E. et al. (2004). “The high prevalence of overweight and obesity in Mexican children”, Obesity Research, 12 (2), pp. 215-223.Di Bonaventura, Marco et al. (2018). “Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 22 (11), pp. 1-10.Elrod, Susan L., y William D. Stansfield (2010). Schaum’s Outline of Genetics (5a ed.). Nueva York: Mc Graw Hill.Flores-Peña, Yolanda et al. (2011). “Evaluation of the maternal perception of her child´s weight and body mass index heritability in mestizas dyads in Southeastern Mexico”, Archivos Latinoamericanos de Nutrición, 61 (4), pp. 389-395._____ (2014). “Homogeneity of maternal perception of child weight in Northeastern Mexico”. The Anthropologist, 17 (3), pp. 991-1001.Liu, Yong-Jun et al. (2003). “Molecular and genetic mechanisms of obesity: implications for future management”. Current Molecular Medicine, 3, pp. 325-340.Maes, Hermine H. et al. (1997). “Genetic and environmental factors in relative body weight and human adiposity”. Behavior Genetics, 27, pp. 325-351.Mechanick, Jeffrey I. et al. (2017). “Adiposity-Based Chronic Disease as a new diagnostic term: The American Association of Clinical Endocrinologists and American College of Endocrinology position statement”. Endocrine Practice, 23 (3), pp. 372-378.ton in Forensic Medicine. Springfield:Charles C. Thomas Publisher.Nelson, Tracy L. et al. (1999). “Genetic and environmental influences on waist-to hip ratio and waist circumference in an older Swedish twin population”. International Journal of Obesity and Related Metabolic Disorders, 23, pp. 449-455.Peraza-González, Irma (2010). Epidemiologia genética de la obesidad en familias nucleares de Mazatlán (tesis de maestría). Universidad Autónoma de Nuevo León, Monterrey.Rankinen, Tuomo et al. (2006). “The human obesity gene map: the 2005 update”. Obesity Research, 14 (4), pp. 529-644.Rose, Kathryn M. et al. (1998). “Genetic and behavioral determinants of waist-hip ratio and waist circumference in women twins”. Obesity Research, 6 (6), pp. 383-92.Sánchez-Castillo, Claudia P. et al. (2001). “Unusually high prevalence rates of obesity in four Mexican rural communities”. European Journal of Clinical Nutrition, 55, pp. 833-40._____ (2002). “Epidemiología de la obesidad”. En Nahúm Méndez y Misael Uribe, Obesidad, epidemiología, fisiopatología y manifestaciones clínicas (pp. 5-31). México: El Manual Moderno.Secretaría de Salud (2001). Programa Nacional de Salud 2001-2006. México: Secretaría de Salud.Snyder, Emily E. et al. (2004). “The human obesity gene map: the 2003 update”. Obesity Research, 12, pp. 369-439.Stunkard Albert J., y Thomas A. Wadden (eds.) (1993). Obesity: theory and therapy (2a ed). Nueva York: Raven Press.Walder Ken et al. (2000). “An autosomal genomic scan for loci linked to plasma leptin concentration in Pima Indians”. International Journal of Obesity and Related Metabolic Disorders, 24, pp. 559-565